Are blood cytokines reliable biomarkers of allergic disease diagnosis and treatment responses? - 04/08/22

Doi : 10.1016/j.jaci.2022.06.008

Susanne Radonjic-Hoesli, MD, PhD ^a, Nikolay Pavlov, MD ^b, Hans-Uwe Simon, MD, PhD ^c,^d, Dagmar Simon, MD ^a,^⁎
^a Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland
^b Department of Pneumology, Inselspital, Bern University Hospital, Bern, Switzerland
^c Institute of Pharmacology, University of Bern, Neuruppin, Germany
^d Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany

^∗Corresponding author: Dagmar Simon, MD, Department of Dermatology, Inselspital, 3010 Bern, Switzerland.Department of DermatologyInselspitalBern3010Switzerland

Abstract

With the development of targeted therapies for allergic diseases, the need for biomarkers supporting disease diagnosis and management has increased. Recent research has elucidated the pattern of cytokines and their distinct roles in the pathogenesis of allergic diseases. This means that cytokines should be considered as biomarkers. In this review article, we summarize published findings and critically discuss the use of cytokine measurements in association with disease diagnosis and management. Among the variety of suggested cytokines, thymus and activation-regulated chemokine (TARC) stands out and can indeed serve as a biomarker of atopic dermatitis. Both biologic characteristics and technical issues determine the reliability and limit the use of blood cytokines as biomarkers.

Le texte complet de cet article est disponible en PDF.

Key words : Atopic dermatitis, asthma, biomarker, thymus and activation-regulated chemokine, eosinophilic esophagitis, urticaria

Abbreviations used : AD, ASST, CCL, CRS, CSU, EoE, TARC, TSLP, VEGF

Plan

Research of H.-U.S. is supported by the Swiss National Science Foundation, Switzerland (grant 310030_184816).

Disclosure of potential conflict of interest: D. Simon reports a relationship with AbbVie, AstraZeneca, Galderma SA, LEO, Eli Lilly, Pfizer, and Sanofi that includes consulting or advising, speaking, and lecture fees. H.-U. Simon reports a relationship with GlaxoSmithKline and AstraZeneca that includes consulting or advising. N. Pavlov reports a relationship with AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Olympus, OM Pharma, and Sanofi that includes consulting or advising and speaker fees. The remaining author declares that she has no relevant conflicts of interest.